{"pmid":32283128,"title":"Should anti-diabetic medications be reconsidered amid COVID-19 pandemic?","text":["Should anti-diabetic medications be reconsidered amid COVID-19 pandemic?","Diabetes Res Clin Pract","Pal, Rimesh","Bhadada, Sanjay K","32283128"],"journal":"Diabetes Res Clin Pract","authors":["Pal, Rimesh","Bhadada, Sanjay K"],"date":"2020-04-14T11:00:00Z","year":2020,"_id":"32283128","week":"202016|Apr 13 - Apr 19","doi":"10.1016/j.diabres.2020.108146","keywords":["Angiotensin-converting enzyme 2","COVID-19, T2DM","Diabetes Mellitus"],"source":"PubMed","topics":["Treatment","Mechanism"],"weight":1,"_version_":1663989232671129601,"score":7.979339,"similar":[{"pmid":32228322,"title":"COVID-19 Pandemic, Corona Viruses, and Diabetes Mellitus.","text":["COVID-19 Pandemic, Corona Viruses, and Diabetes Mellitus.","The pandemic of COVID-19, a disease caused by a novel coronavirus (CoV), SARS-CoV-2, is causing substantial morbidity and mortality. Older age and presence of diabetes mellitus, hypertension, and obesity significantly increases the risk for hospitalization and death in COVID-19 patients. In this Perspective, informed by the studies on severe acute respiratory syndrome, SARS-CoV, and Middle East respiratory syndrome, MERS-CoV, and the current literature on SARS-CoV-2, we discuss potential mechanisms by which diabetes modulates the host-viral interactions and host-immune responses. We hope to highlight gaps in knowledge that require further studies pertinent to COVID-19 in patients with diabetes.","Am J Physiol Endocrinol Metab","Muniyappa, Ranganath","Gubbi, Sriram","32228322"],"abstract":["The pandemic of COVID-19, a disease caused by a novel coronavirus (CoV), SARS-CoV-2, is causing substantial morbidity and mortality. Older age and presence of diabetes mellitus, hypertension, and obesity significantly increases the risk for hospitalization and death in COVID-19 patients. In this Perspective, informed by the studies on severe acute respiratory syndrome, SARS-CoV, and Middle East respiratory syndrome, MERS-CoV, and the current literature on SARS-CoV-2, we discuss potential mechanisms by which diabetes modulates the host-viral interactions and host-immune responses. We hope to highlight gaps in knowledge that require further studies pertinent to COVID-19 in patients with diabetes."],"journal":"Am J Physiol Endocrinol Metab","authors":["Muniyappa, Ranganath","Gubbi, Sriram"],"date":"2020-04-02T11:00:00Z","year":2020,"_id":"32228322","week":"202014|Mar 30 - Apr 05","doi":"10.1152/ajpendo.00124.2020","keywords":["COVID-19","Coronavirus","Diabetes Mellitus"],"source":"PubMed","topics":["Mechanism"],"weight":1,"_version_":1663352135339737088,"score":111.77594},{"pmid":32274570,"title":"COVID-19 in the heart and the lungs: could we \"Notch\" the inflammatory storm?","text":["COVID-19 in the heart and the lungs: could we \"Notch\" the inflammatory storm?","From January 2020, coronavirus disease (COVID-19) originated in China has spread around the world. The disease is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The presence of myocarditis, cardiac arrest, and acute heart failure in COVID-19 patients suggests the existence of a relationship between SARS-CoV-2 infection and cardiac disease. The Notch signalling is a major regulator of cardiovascular function and it is also implicated in several biological processes mediating viral infections. In this report we discuss the possibility to target Notch signalling to prevent SARS-CoV-2 infection and interfere with the progression of COVID-19- associated heart and lungs disease.","Basic Res Cardiol","Rizzo, Paola","Vieceli Dalla Sega, Francesco","Fortini, Francesca","Marracino, Luisa","Rapezzi, Claudio","Ferrari, Roberto","32274570"],"abstract":["From January 2020, coronavirus disease (COVID-19) originated in China has spread around the world. The disease is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The presence of myocarditis, cardiac arrest, and acute heart failure in COVID-19 patients suggests the existence of a relationship between SARS-CoV-2 infection and cardiac disease. The Notch signalling is a major regulator of cardiovascular function and it is also implicated in several biological processes mediating viral infections. In this report we discuss the possibility to target Notch signalling to prevent SARS-CoV-2 infection and interfere with the progression of COVID-19- associated heart and lungs disease."],"journal":"Basic Res Cardiol","authors":["Rizzo, Paola","Vieceli Dalla Sega, Francesco","Fortini, Francesca","Marracino, Luisa","Rapezzi, Claudio","Ferrari, Roberto"],"date":"2020-04-11T11:00:00Z","year":2020,"_id":"32274570","week":"202015|Apr 06 - Apr 12","doi":"10.1007/s00395-020-0791-5","keywords":["ADAM17","Angiotensin-converting enzyme 2","COVID-19","Cardiovascular disease","Coronavirus disease","Furin","Notch"],"source":"PubMed","locations":["China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Mechanism","Treatment"],"weight":1,"_version_":1663712077829636097,"score":85.501175},{"pmid":32267499,"title":"The role of angiotensin-converting enzyme 2 in coronaviruses/influenza viruses and cardiovascular disease.","text":["The role of angiotensin-converting enzyme 2 in coronaviruses/influenza viruses and cardiovascular disease.","Angiotensin-converting enzyme 2 (ACE2) has emerged as a key regulator of the renin-angiotensin system in cardiovascular (CV) disease and plays a pivotal role in infections by coronaviruses and influenza viruses. The present review is primarily focused on the findings to indicate the role of ACE2 in the relationship of coronaviruses and influenza viruses to CV disease. It is postulated that the risk of coronavirus or influenza virus infection is high, at least partly due to high ACE2 expression in populations with a high CV risk. Coronavirus and influenza virus vaccine usage in high CV risk populations could be a potential strategy to prevent both CV disease and coronavirus/influenza virus infections.","Cardiovasc Res","Chen, Li","Hao, Guang","32267499"],"abstract":["Angiotensin-converting enzyme 2 (ACE2) has emerged as a key regulator of the renin-angiotensin system in cardiovascular (CV) disease and plays a pivotal role in infections by coronaviruses and influenza viruses. The present review is primarily focused on the findings to indicate the role of ACE2 in the relationship of coronaviruses and influenza viruses to CV disease. It is postulated that the risk of coronavirus or influenza virus infection is high, at least partly due to high ACE2 expression in populations with a high CV risk. Coronavirus and influenza virus vaccine usage in high CV risk populations could be a potential strategy to prevent both CV disease and coronavirus/influenza virus infections."],"journal":"Cardiovasc Res","authors":["Chen, Li","Hao, Guang"],"date":"2020-04-09T11:00:00Z","year":2020,"_id":"32267499","week":"202015|Apr 06 - Apr 12","doi":"10.1093/cvr/cvaa093","keywords":["Angiotensin-converting enzyme 2","Cardiovascular disease","Coronaviruses","Influenza viruses"],"source":"PubMed","topics":["Treatment"],"weight":1,"_version_":1663609715834224640,"score":64.6524},{"pmid":32233018,"title":"Covid-19 and diabetes mellitus: unveiling the interaction of two pandemics.","text":["Covid-19 and diabetes mellitus: unveiling the interaction of two pandemics.","A novel RNA betacoronavirus causing coronavirus disease 2019 (Covid-19) has now been declared pandemic disease by WHO. Guo W et al published the first report of biochemical features in patients with diabetes and the further risk that this disease can determine to the progression of Covid-19. Among different cytokines found significantly higher in patients with diabetes compared to those without, Interleukin-6 (IL-6) which is already increased in conditions of chronic inflammation, may play a more deleterious role in Covid-19 infection. Targeting the over expression of Il-6 effects with a monoclonal antibody against IL-6 receptor or using Janus Kinase inhibitors may be particularly helpful for treatment of Covid-19 pneumonia in diabetes. This article is protected by copyright. All rights reserved.","Diabetes Metab Res Rev","Maddaloni, Ernesto","Buzzetti, Raffaella","32233018"],"abstract":["A novel RNA betacoronavirus causing coronavirus disease 2019 (Covid-19) has now been declared pandemic disease by WHO. Guo W et al published the first report of biochemical features in patients with diabetes and the further risk that this disease can determine to the progression of Covid-19. Among different cytokines found significantly higher in patients with diabetes compared to those without, Interleukin-6 (IL-6) which is already increased in conditions of chronic inflammation, may play a more deleterious role in Covid-19 infection. Targeting the over expression of Il-6 effects with a monoclonal antibody against IL-6 receptor or using Janus Kinase inhibitors may be particularly helpful for treatment of Covid-19 pneumonia in diabetes. This article is protected by copyright. All rights reserved."],"journal":"Diabetes Metab Res Rev","authors":["Maddaloni, Ernesto","Buzzetti, Raffaella"],"date":"2020-04-02T11:00:00Z","year":2020,"_id":"32233018","week":"202014|Mar 30 - Apr 05","doi":"10.1002/dmrr.3321","keywords":["Covid-19","Diabetes","Inflammation; IL-6"],"source":"PubMed","locations":["Janus"],"topics":["Mechanism","Treatment"],"weight":1,"_version_":1663352135364902912,"score":61.340458},{"pmid":32119961,"pmcid":"PMC7089605","title":"Anti-HCV, nucleotide inhibitors, repurposing against COVID-19.","text":["Anti-HCV, nucleotide inhibitors, repurposing against COVID-19.","AIMS: A newly emerged Human Coronavirus (HCoV) is reported two months ago in Wuhan, China (COVID-19). Until today >2700 deaths from the 80,000 confirmed cases reported mainly in China and 40 other countries. Human to human transmission is confirmed for COVID-19 by China a month ago. Based on the World Health Organization (WHO) reports, SARS HCoV is responsible for >8000 cases with confirmed 774 deaths. Additionally, MERS HCoV is responsible for 858 deaths out of about 2500 reported cases. The current study aims to test anti-HCV drugs against COVID-19 RNA dependent RNA polymerase (RdRp). MATERIALS AND METHODS: In this study, sequence analysis, modeling, and docking are used to build a model for Wuhan COVID-19 RdRp. Additionally, the newly emerged Wuhan HCoV RdRp model is targeted by anti-polymerase drugs, including the approved drugs Sofosbuvir and Ribavirin. KEY FINDINGS: The results suggest the effectiveness of Sofosbuvir, IDX-184, Ribavirin, and Remidisvir as potent drugs against the newly emerged HCoV disease. SIGNIFICANCE: The present study presents a perfect model for COVID-19 RdRp enabling its testing in silico against anti-polymerase drugs. Besides, the study presents some drugs that previously proved its efficiency against the newly emerged viral infection.","Life Sci","Elfiky, Abdo A","32119961"],"abstract":["AIMS: A newly emerged Human Coronavirus (HCoV) is reported two months ago in Wuhan, China (COVID-19). Until today >2700 deaths from the 80,000 confirmed cases reported mainly in China and 40 other countries. Human to human transmission is confirmed for COVID-19 by China a month ago. Based on the World Health Organization (WHO) reports, SARS HCoV is responsible for >8000 cases with confirmed 774 deaths. Additionally, MERS HCoV is responsible for 858 deaths out of about 2500 reported cases. The current study aims to test anti-HCV drugs against COVID-19 RNA dependent RNA polymerase (RdRp). MATERIALS AND METHODS: In this study, sequence analysis, modeling, and docking are used to build a model for Wuhan COVID-19 RdRp. Additionally, the newly emerged Wuhan HCoV RdRp model is targeted by anti-polymerase drugs, including the approved drugs Sofosbuvir and Ribavirin. KEY FINDINGS: The results suggest the effectiveness of Sofosbuvir, IDX-184, Ribavirin, and Remidisvir as potent drugs against the newly emerged HCoV disease. SIGNIFICANCE: The present study presents a perfect model for COVID-19 RdRp enabling its testing in silico against anti-polymerase drugs. Besides, the study presents some drugs that previously proved its efficiency against the newly emerged viral infection."],"journal":"Life Sci","authors":["Elfiky, Abdo A"],"date":"2020-03-03T11:00:00Z","year":2020,"_id":"32119961","week":"202010|Mar 02 - Mar 08","doi":"10.1016/j.lfs.2020.117477","keywords":["COVID-19","Docking","Nucleotide inhibitors","RdRp","Sofosbuvir","Structural bioinformatics","Wuhan coronavirus"],"source":"PubMed","locations":["Sofosbuvir","Wuhan","China","Ribavirin"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Treatment","Mechanism"],"weight":1,"e_drugs":["Sofosbuvir","IDX184","Ribavirin"],"_version_":1663352134315278336,"score":61.03479}]}